These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 30610681)
1. Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease? Nicholls SJ; Nelson AJ Am J Cardiovasc Drugs; 2019 Jun; 19(3):229-235. PubMed ID: 30610681 [TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987 [TBL] [Abstract][Full Text] [Related]
3. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week. Armitage J; Holmes MV; Preiss D J Am Coll Cardiol; 2019 Feb; 73(4):477-487. PubMed ID: 30704580 [TBL] [Abstract][Full Text] [Related]
4. Cholesteryl ester transfer protein (CETP) inhibitors. Hunt JA; Lu Z Curr Top Med Chem; 2009; 9(5):419-27. PubMed ID: 19519458 [TBL] [Abstract][Full Text] [Related]
5. Refocusing on use of cholesteryl ester transfer protein inhibitors. Kastelein JJ Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853 [TBL] [Abstract][Full Text] [Related]
6. [High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning]. Kleber ME; Grammer TB; März W MMW Fortschr Med; 2010 Jul; 152 Suppl 2():47-55. PubMed ID: 21591319 [TBL] [Abstract][Full Text] [Related]
7. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk. Mantlo NB; Escribano A J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686 [TBL] [Abstract][Full Text] [Related]
8. Anacetrapib as a potential cardioprotective strategy. Di Bartolo BA; Nicholls SJ Drug Des Devel Ther; 2017; 11():3497-3502. PubMed ID: 29263647 [TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of CETP inhibitors: a patent review. Wang X; Li W; Hao L; Xie H; Hao C; Liu C; Li W; Xiong X; Zhao D Expert Opin Ther Pat; 2018 Apr; 28(4):331-340. PubMed ID: 29424255 [TBL] [Abstract][Full Text] [Related]
10. Structural and biophysical insight into cholesteryl ester-transfer protein. Hall J; Qiu X Biochem Soc Trans; 2011 Aug; 39(4):1000-5. PubMed ID: 21787337 [TBL] [Abstract][Full Text] [Related]
11. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Neeli H; Rader DJ Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230 [TBL] [Abstract][Full Text] [Related]
12. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344 [TBL] [Abstract][Full Text] [Related]
13. The potential for CETP inhibition to reduce cardiovascular disease risk. Ansell B; Hobbs FD Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461 [TBL] [Abstract][Full Text] [Related]
14. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? Barter P; Rye KA Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767 [TBL] [Abstract][Full Text] [Related]